Mark E. Goldman

7.2k total citations · 1 hit paper
103 papers, 6.0k citations indexed

About

Mark E. Goldman is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Mark E. Goldman has authored 103 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 21 papers in Oncology and 20 papers in Genetics. Recurrent topics in Mark E. Goldman's work include Estrogen and related hormone effects (16 papers), HIV/AIDS drug development and treatment (16 papers) and Receptor Mechanisms and Signaling (10 papers). Mark E. Goldman is often cited by papers focused on Estrogen and related hormone effects (16 papers), HIV/AIDS drug development and treatment (16 papers) and Receptor Mechanisms and Signaling (10 papers). Mark E. Goldman collaborates with scholars based in United States, Belgium and Switzerland. Mark E. Goldman's co-authors include Donald P. McDonnell, D. P. McDonnell, Elisabetta Vegeto, Dale E. Mais, B W O'Malley, J. M. HOFFMAN, J A O'Brien, Emilio A. Emini, William A. Schleif and Joanna Pike and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Mark E. Goldman

102 papers receiving 5.8k citations

Hit Papers

Human progesterone receptor A form is a cell- and promote... 1993 2026 2004 2015 1993 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function.
    1993 641 citations Elisabetta Vegeto, Mark E. Goldman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark E. Goldman United States 39 2.3k 1.8k 919 879 847 103 6.0k
Mike Mueckler United States 55 7.9k 3.4× 1.1k 0.6× 565 0.6× 559 0.6× 796 0.9× 113 12.3k
Ajoy Basak Canada 38 2.4k 1.1× 343 0.2× 492 0.5× 417 0.5× 811 1.0× 116 5.6k
Andreas Billich Austria 42 4.6k 2.0× 420 0.2× 1.1k 1.2× 531 0.6× 386 0.5× 131 6.8k
Walter Becker Germany 46 3.2k 1.4× 949 0.5× 524 0.6× 1.1k 1.2× 549 0.6× 136 6.8k
Yi Liu China 45 5.2k 2.3× 704 0.4× 1.5k 1.6× 395 0.4× 1.3k 1.6× 247 8.4k
Suzanne Benjannet Canada 49 4.0k 1.8× 466 0.3× 822 0.9× 1.3k 1.5× 945 1.1× 107 10.2k
Tur‐Fu Huang Taiwan 45 3.1k 1.4× 2.9k 1.7× 583 0.6× 122 0.1× 414 0.5× 230 7.1k
Pam Fredman Sweden 51 4.3k 1.9× 593 0.3× 1.4k 1.5× 234 0.3× 558 0.7× 177 8.0k
Sophie Roy Canada 43 7.7k 3.4× 562 0.3× 2.1k 2.2× 376 0.4× 1.0k 1.2× 94 10.7k
Manfred Brockhaus Switzerland 49 3.9k 1.7× 499 0.3× 5.1k 5.6× 227 0.3× 1.4k 1.6× 83 10.2k

Countries citing papers authored by Mark E. Goldman

Since Specialization
Citations

This map shows the geographic impact of Mark E. Goldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Goldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Goldman more than expected).

Fields of papers citing papers by Mark E. Goldman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Goldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Goldman. The network helps show where Mark E. Goldman may publish in the future.

Co-authorship network of co-authors of Mark E. Goldman

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Goldman. A scholar is included among the top collaborators of Mark E. Goldman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Goldman. Mark E. Goldman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goldman, Mark E., et al.. (2006). Cationic polyamines inhibit anthrax lethal factor protease. BMC Pharmacology. 6(1). 8–8. 24 indexed citations
2.
Edwards, James P., Robert I. Higuchi, David T. Winn, et al.. (1999). Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one. Bioorganic & Medicinal Chemistry Letters. 9(7). 1003–1008. 42 indexed citations
3.
Edwards, James P., Mark E. Goldman, Ming‐Wei Wang, et al.. (1998). Discovery and Preliminary SAR Studies of a Novel, Nonsteroidal Progesterone Receptor Antagonist Pharmacophore. Journal of Medicinal Chemistry. 41(18). 3461–3466. 37 indexed citations
4.
Hamann, Lawrence G., David T. Winn, Christopher M. Tegley, et al.. (1998). Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines. Bioorganic & Medicinal Chemistry Letters. 8(19). 2731–2736. 19 indexed citations
5.
6.
Kossodo, S de, C Monso, Pierre Juillard, et al.. (1997). Interleukin‐10 modulates susceptibility in experimental cerebral malaria. Immunology. 91(4). 536–540. 153 indexed citations
7.
Goldman, Mark E.. (1997). Book Review. Drug Discovery Today. 2(3). 88–88. 2 indexed citations
8.
Goldman, Mark E., Lynn J. Ransone, David W. Anderson, et al.. (1996). SP100030 is a novel T-cell-specific transcription factor inhibitor that possesses immunosuppressive activity in vivo.. PubMed. 28(6). 3106–9. 11 indexed citations
9.
Hamann, Lawrence G., Luc J. Farmer, Michael G. Johnson, et al.. (1996). Synthesis and Biological Activity of Novel Nonsteroidal Progesterone Receptor Antagonists Based on Cyclocymopol Monomethyl Ether. Journal of Medicinal Chemistry. 39(9). 1778–1789. 31 indexed citations
10.
Hamann, Lawrence G., Luc J. Farmer, Michael G. Johnson, et al.. (1995). Synthesis and Biological Activity of Novel Nonsteroidal Progesterone Receptor Antagonists. Annals of the New York Academy of Sciences. 761(1). 383–387. 5 indexed citations
11.
McDonnell, Donald P., et al.. (1994). The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional acitivity. The Journal of Steroid Biochemistry and Molecular Biology. 48(5-6). 425–432. 133 indexed citations
12.
Boehm, Marcus F., Michael McClurg, Charles Pathirana, et al.. (1994). Synthesis of high specific activity tritium-labeled [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties. Journal of Medicinal Chemistry. 37(3). 408–414. 69 indexed citations
13.
HOFFMAN, J. M., et al.. (1992). Synthesis and evaluation of 2-pyridinone derivatives as HIV-1 specific reverse transcriptase inhibitors. 1. Phthalimidoalkyl and -alkylamino analogs. Journal of Medicinal Chemistry. 35(21). 3784–3791. 44 indexed citations
14.
Cushman, Mark, et al.. (1991). Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds. Journal of Medicinal Chemistry. 34(1). 337–342. 52 indexed citations
15.
Chorev, Michael, Roberta L. McKee, Jane E. Reagan, et al.. (1991). Biological activity of parathyroid hormone antagonists substituted at position 13. Peptides. 12(1). 57–62. 13 indexed citations
16.
17.
Caulfield, Michael P., Roberta L. McKee, Mark E. Goldman, et al.. (1990). Parathyroid hormone-related protein (PTHrP): Studies with synthetic peptides indicate that parathyroid hormone and PTHrP interact with the same receptor. International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology. 17(7). 633–637. 3 indexed citations
18.
Mantione, Charles R., Mark E. Goldman, Brian M. Martin, et al.. (1988). Purification and characterization of an endogenous protein modulator of radioligand binding to “peripheral-type” benzodiazepine receptors and dihydropyridine ca2+-channel antagonist binding sites. Biochemical Pharmacology. 37(2). 339–347. 20 indexed citations
19.
Goldman, Mark E. & John J. Pisano. (1985). Inhibition of [3H]nitrendipine binding by phospholipase A2. Life Sciences. 37(14). 1301–1308. 9 indexed citations
20.
Goldman, Mark E., Arthur E. Jacobson, Kenner C. Rice, & Steven M. Paul. (1985). Differentiation of [3H]phencyclidine and ( + )‐[3H]SKF‐10,047 binding sites in rat cerebral cortex. FEBS Letters. 190(2). 333–336. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mike Mueckler Breakdown of academic impact, for papers by Ajoy Basak Breakdown of academic impact, for papers by Andreas Billich Breakdown of academic impact, for papers by Walter Becker Breakdown of academic impact, for papers by Yi Liu Breakdown of academic impact, for papers by Suzanne Benjannet Breakdown of academic impact, for papers by Tur‐Fu Huang Breakdown of academic impact, for papers by Pam Fredman Breakdown of academic impact, for papers by Sophie Roy Breakdown of academic impact, for papers by Manfred Brockhaus
Rankless by CCL
2026